Launching White Paper on CLL immune-related challenges
The big day has arrived!
We are delighted to announce that CLL Advocates Network (CLLAN), in partnership with AstraZeneca, has worked with global experts and advocates to develop a White Paper titled “Compromised: Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia (CLL)” which we are launching today.
As we all know, the COVID-19 pandemic has shone a spotlight on the varied immune challenges, in addition to infections, that people with CLL face. This forms a major part of managing day-to-day life with CLL and has long been overlooked in CLL management and care.
We are immensely proud of the paper which sets out recommendations needed to achieve improvement in the management of immune challenges for CLL patients.
The report highlights the following 4 key recommendations:
- Creating global clinical guidance for monitoring and managing immunosuppression in people with CLL
- Ensuring that immunocompromised status is flagged in the patient health records of people with CLL
- Instigating education and awareness raising activities amongst healthcare professionals, especially primary care physicians
- Making shared decision-making and personalised approaches commonplace in the management and care of people with CLL
We are incredibly grateful to all the individuals and organisations who have contributed to co-create this one of a kind new White Paper.
Please spread the word with your members, colleagues and wider network!
To read the full white paper please click here:
www.clladvocates.net/whitepaper-CLL-immune-challenges/